New Delhi, July 8 -- Vertex Pharmaceuticals is making its largest acquisition ever, placing a massive $10 billion bet on rare endocrine diseases with the purchase of Crinetics Pharmaceuticals. The deal marks a major strategic shift for the biotechnology leader, which has built its empire around cystic fibrosis treatments but is now expanding aggressively into new high-value therapeutic areas.

Under the agreement, Vertex will acquire Crinetics for $85 per share in cash, representing an equity value of approximately $10 billion. The transaction is expected to close in the third quarter of 2026 after receiving customary regulatory approvals.

The acquisition gives Vertex access to Crinetics' growing endocrine portfolio, including PALSONIFY,...